Dynamic Technology Lab Private Ltd Buys Shares of 8,218 Globus Medical, Inc. (NYSE:GMED)

Dynamic Technology Lab Private Ltd bought a new stake in Globus Medical, Inc. (NYSE:GMED - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 8,218 shares of the medical device company's stock, valued at approximately $680,000.

Several other large investors also recently bought and sold shares of the stock. SBI Securities Co. Ltd. purchased a new position in Globus Medical during the 4th quarter worth $27,000. Quarry LP grew its stake in shares of Globus Medical by 698.4% during the 3rd quarter. Quarry LP now owns 495 shares of the medical device company's stock worth $35,000 after purchasing an additional 433 shares during the period. UMB Bank n.a. lifted its position in shares of Globus Medical by 60.2% during the 4th quarter. UMB Bank n.a. now owns 548 shares of the medical device company's stock valued at $45,000 after acquiring an additional 206 shares during the period. V Square Quantitative Management LLC boosted its position in Globus Medical by 52.0% during the fourth quarter. V Square Quantitative Management LLC now owns 576 shares of the medical device company's stock worth $48,000 after purchasing an additional 197 shares in the last quarter. Finally, First Horizon Advisors Inc. grew its stake in Globus Medical by 24.7% in the 4th quarter. First Horizon Advisors Inc. now owns 666 shares of the medical device company's stock valued at $55,000 after acquiring an additional 132 shares during the last quarter. Institutional investors and hedge funds own 95.16% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on GMED. Stifel Nicolaus upped their target price on Globus Medical from $92.00 to $94.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Barclays increased their price objective on Globus Medical from $100.00 to $103.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. Bank of America raised shares of Globus Medical from an "underperform" rating to a "neutral" rating and boosted their target price for the company from $80.00 to $97.00 in a research note on Thursday, January 9th. Wells Fargo & Company decreased their price target on shares of Globus Medical from $95.00 to $93.00 and set an "overweight" rating on the stock in a research note on Friday, February 21st. Finally, Canaccord Genuity Group boosted their price objective on shares of Globus Medical from $92.00 to $101.00 and gave the company a "buy" rating in a research report on Friday, January 10th. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $96.91.

Globus Medical Stock Performance

Globus Medical stock traded up $1.77 during midday trading on Friday, reaching $72.75. The stock had a trading volume of 1,158,621 shares, compared to its average volume of 1,043,790. The stock's 50-day simple moving average is $77.20 and its 200 day simple moving average is $80.07. The stock has a market capitalization of $10.01 billion, a PE ratio of 97.00, a price-to-earnings-growth ratio of 1.61 and a beta of 1.28. Globus Medical, Inc. has a twelve month low of $49.33 and a twelve month high of $94.93.

Globus Medical (NYSE:GMED - Get Free Report) last announced its earnings results on Thursday, February 20th. The medical device company reported $0.84 EPS for the quarter, beating the consensus estimate of $0.74 by $0.10. The business had revenue of $657.29 million for the quarter, compared to the consensus estimate of $646.19 million. Globus Medical had a return on equity of 10.83% and a net margin of 4.09%. Equities analysts predict that Globus Medical, Inc. will post 3.44 earnings per share for the current fiscal year.

Globus Medical Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.